Sign in
EDIT Stock Price, Chart, Stats & News
Editas Medicine, Inc.
Save
Editas Medicine, Inc. (EDIT) does not currently pay a dividend.
309.36M
Market cap
–
Current P/E
–
Forward P/E
EDIT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -410.34% |
Pretax margin | -395.01% |
Net margin | -395.01% |
Effective tax rate | – |
ROA | -85.81% |
ROE | -523.29% |
D/E | 2.81x |
Interest coverage ratio | – |
EDIT valuation
P/E | – |
P/S | 5.39x |
P/B | 7.25x |
P/CF | -1.20x |
P/FCF | -1.32x |
P/OCF | -1.20x |
PEG | -0.06x |
EV multiple | -1.94x |
About
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
Similar securities
Based on sector and market capitalization
Report issue